(3aS)-palonosetron
Also known as (3aS)-2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a, 4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one, (3aS)-2,3,3a,4,5,6-hexahydro-2-[(3S)-3-quinuclidinyl]-1H-benz[de]isoquinolin-1-one, palonosetron, [R-(R*,R*)]-2-(1-azabicyclo[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one
Palonosetron, sold under the brand name Aloxi, is a medication used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is a 5-HT3 antagonist.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 464197120
- Drug.image
- Palonosetron structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.tradename
- Aloxi
- Drug.MedlinePlus
- a610002
- Drug.DailyMedID
- Palonosetron
- Drug.pregnancy_AU
- B1
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
Article
9 sectionsContents
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- Society and culture
- Economics
- References
Palonosetron, sold under the brand name Aloxi, is a medication used for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is a 5-HT3 antagonist.
Palonosetron is administered intravenously, or as a single oral capsule. It has a longer duration of action than other 5-HT3 antagonists. The oral formulation was approved on in August 2008, for prevention of acute CINV alone, as a large clinical trial did not show oral administration to be as effective as intravenous use against delayed CINV. Palonosetron is a therapeutic alternative on the World Health Organization's List of Essential Medicines.